PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29279550-8	2017	For targeted therapies, an anti-CD30 monoclonal antibody linked to a synthetic antimitotic agent (brentuximab vedotin) and ALK inhibitors (crizotinib, alectinib, and ceritinib) are being used in clinical settings.	Crizotinib	139-149	TNF receptor superfamily member 8	Homo sapiens	32-36	
30742941-0	2019	Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.	Crizotinib	0-10	TNF receptor superfamily member 8	Homo sapiens	25-29	
30742941-3	2019	In vitro, anti-CD30-LDM showed strong synergistic antiproliferative activity when combined with crizotinib.	Crizotinib	96-106	TNF receptor superfamily member 8	Homo sapiens	15-19	
30742941-6	2019	Interestingly, the addition of crizotinib inhibited the expression of phosphorylated ERK1/2 and further augmented anti-CD30-LDM-mediated apoptosis, providing a potential synergistic mechanism for DNA-damaging agents combined with NPM-ALK inhibitors.	Crizotinib	31-41	TNF receptor superfamily member 8	Homo sapiens	119-123	
30742941-8	2019	This research demonstrated for the first time that the combination of anti-CD30-LDM and crizotinib exhibits a synergistic inhibitory effect in tumor cells.	Crizotinib	88-98	TNF receptor superfamily member 8	Homo sapiens	75-79